PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2012
CASE
AUTH/2559/11/12 Orion Pharma

AUTH/2559/11/12: Orion Pharma UK – Sponsorship of ISU meeting at 5-star Belfast venue (Clause 9.1 breach)

Orion supported an ISU urology meeting in Belfast held at a 5-star venue with golf and a gala dinner referenced in the…

2013
CASE
AUTH/2604/5/13 Sanofi

Novo Nordisk v Sanofi: Lyxumia ad ruled misleading for β€œonly once-daily” positioning and cost-minimisation claims (AUTH/2604/5/13)

Sanofi’s Lyxumia Health Service Journal ad breached the ABPI Code after β€œonly once-daily” wording and β€œminimises costs/cost savings” claims were found misleading…

2013
CASE
AUTH/2580/2/13 Gedeon Richter

Gedeon Richter: Esmya meeting invitation ruled promotional without prescribing information (AUTH/2580/2/13)

An Esmya-linked meeting invitation was deemed promotional due to brand imagery and content, but lacked prescribing information (breach Clause 4.1). Allegations of…

2013
CASE
AUTH/2634/8/13 Boehringer Ingelheim

AUTH/2634/8/13: Anonymous v Boehringer Ingelheim – Spiriva Respimat β€˜perfectly safe’ claim (No breach)

Anonymous GP alleged a Boehringer Ingelheim rep said Spiriva Respimat was β€œperfectly safe” based on an unpublished study. Panel found the allegation…

2013
CASE
AUTH/2600/4/13 Sanofi ⭐ Case of the Week

AUTH/2600/4/13: Novo Nordisk v Sanofi – Lyxumia β€˜only once-daily prandial GLP‑1’ and other claims ruled misleading/exaggerated

Sanofi’s Lyxumia materials claimed it was the β€œonly once-daily prandial GLP‑1”, plus broad benefit and β€œstrong evidence” statements. PMCPA ruled the claims…

2014
CASE
AUTH/2701/2/14 GlaxoSmithKline

AUTH/2701/2/14: Anonymous GP v GlaxoSmithKline (Relvar Ellipta journal advertisements) – No breach

Anonymous GP challenged two ad claims for Relvar Ellipta (β€œDelivered in a straightforward device” and β€œThat offers value to the NHS”). PMCPA…

2015
CASE
Bausch

ALK-AbellΓ³ v Bausch & Lomb: Pulse Quick Guide breached Code by using β€œnew” for an established dose

A Pulse Quick Guide funded by Bausch & Lomb described Emerade as offering a β€œnew higher dose” even though the 500mcg dose…

2016
CASE
AUTH/2818/1/16 Pfizer

Pfizer: webinar invitation email found to be disguised promotion and sponsorship not clear at the outset (AUTH/2818/1/16)

A CCG complained about a third‑party webinar invite for Sayana Press. Panel found the email’s promotional nature was disguised and Pfizer’s sponsorship…

2015
CASE
AUTH/2786/8/15 UCB Pharma

AUTH/2786/8/15: Keppra medical information email reposted on ESNA website β€” UCB found not responsible (No breach)

A UCB medical information email about Keppra vs generic levetiracetam appeared on the ESNA nurses’ website without attribution. Panel accepted it was…

2015
CASE
Boehringer Ingelheim ⭐ Case of the Week

Boehringer Ingelheim breached Clauses 7.2 and 7.8 over unclear simulated dosing graph on congress stand (Pradaxa)

A congress-stand presentation included a dosing/missed-dose graph that wasn’t clearly labelled as simulated or properly attributed. The Panel found it misleading (Clauses…

2014
CASE
AUTH/2738/10/14 Boehringer Ingelheim

Boehringer Ingelheim: Global LinkedIn InMail promoting Giotrif reached UK recipients without UK certification or mandatory information (AUTH/2738/10/14)

A Germany-sent LinkedIn InMail promoting Giotrif reached UK recipients. It lacked UK certification, prescribing info, AE reporting and black triangle, used unbalanced/misleading…

2014
CASE
AUTH/2723/7/14 Napp Pharmaceuticals

Napp Pharmaceuticals: BuTrans β€˜pain in dementia’ campaign ruled misleading and unsubstantiated (AUTH/2723/7/14)

A clinician challenged BuTrans dementia-focused promotion. PMCPA ruled website/detail aid misleading and unsubstantiated for analgesic efficacy and implied antipsychotic reduction; BMJ ad…

2014
CASE
AUTH/2708/4/14 ProStrakan

ProStrakan: osteoporosis therapy review service alleged to be misrepresented as CCG-approved (AUTH/2708/4/14)

NHS employee alleged GP practices were misled that a ProStrakan-sponsored osteoporosis therapy review (via a third party) was CCG-approved/continuation of a prior…

2013
CASE
AUTH/2662/11/13 Novartis Pharmaceuticals UK

AUTH/2662/11/13: Novartis breach for delayed clinical trial results disclosure (Ilaris); no breach for Gilenya legacy trial

Public complaint about clinical trial transparency data for Ilaris and Gilenya. PMCPA found one Ilaris trial result was disclosed late (breach Clauses…

2016
CASE
AUTH/2839/4/16 Merck Sharp & Dohme ⭐ Case of the Week

AUTH/2839/4/16: Anonymous v Merck Sharp & Dohme β€” Diabetes nurses study day sponsorship (No breach)

Anonymous complaint alleged MSD funded speakers and effectively ran a diabetes nurses study day without clear disclosure. Panel found no evidence, confirmed…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training